Edwards Lifesciences EW Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $380.7M+6.8% | $91.2M-76.3% | $290.3M-90.5% | $331.5M-9.2% | $356.4M+1.5% | ||
| $40.9M+11.7% | $42.7M+0.2% | $39.2M+13.6% | $38.1M-3.8% | $36.6M-4.9% | ||
| $45.4M+12.9% | $39.2M+23.7% | $41.2M-2.1% | $37.5M-14.6% | $40.2M-9.9% | ||
| $1.6M+1,500% | -$11M-121% | $0-100% | -$41.6M-144% | $100K-99.9% | ||
| -$347.1M-236% | $168.7M— | $226.1M+656% | $103.7M-31.7% | -$103.4M-16.0% | ||
| $18.1M-36.7% | $2.7M-84.4% | $7.9M— | —— | $28.6M+581% | ||
| $41.9M-18.2% | —— | -$10.2M-102% | -$240.4M-125% | $51.2M+119% | ||
| $43.8M-84.4% | $450.9M— | $573.7M+63.1% | $290.2M-21.9% | $280.4M+624% | ||
| $64.9M+15.9% | $97.4M+95.6% | $57.5M+10.8% | $49.3M-42.3% | $56M-14.2% | ||
| $6.3M— | $15M-45.3% | $1.5M-94.4% | $48.3M— | $0— | ||
| $641.1M+1.0% | $826.6M+117% | $1.01B+94.7% | $624.3M— | $634.5M+35,150% | ||
| $12.5M-29.4% | $7.9M+11.3% | $22.2M-11.9% | $14.3M-10.1% | $17.7M+90.3% | ||
| -$92.8M-209% | -$198.3M— | -$427.8M-116% | -$172.1M-238% | $85.3M+35.2% | ||
| $421.8M+63.1% | $40.6M-59.4% | $588.7M-34.7% | $5.5M-96.5% | $258.6M+129,200% | ||
| -$451.2M-74.9% | -$11.4M— | -$740.1M+24.2% | $0+100% | -$258M-518% | ||
| $8.2M+146% | $0-100% | -$1M+98.1% | -$29.6M-201% | -$17.7M-282% | ||
| -$492M-647% | —— | -$595.2M-129% | $141.2M-67.1% | $90M+11.1% | ||
| $123.6M— | —— | —— | $47.1M— | $0— | ||
| $65.2M— | $0-100% | —— | —— | $0— | ||
| -$3.5M+72.0% | —— | —— | —— | -$12.5M-1,350% | ||
| $117.9M+170% | —— | —— | $24.9M+208% | $43.7M-20.5% | ||
| -$9.4M-139% | $54.4M-44.8% | $18M-85.4% | $20.9M-68.4% | $24.3M-32.1% | ||
| -$50M-36.2% | -$14.8M-18.4% | -$12.5M0.0% | -$12.5M-89.4% | -$36.7M-606% | ||
| $8.7M+182% | $6.2M— | $14.2M— | $13.9M+207% | -$10.6M+60.9% | ||
| $6.5M+6.6% | $6.6M+6.5% | $6.8M+4.6% | $6.4M-13.5% | $6.1M-20.8% | ||
| -$500K+86.1% | -$5.4M+48.6% | —— | -$4.7M-213% | -$3.6M-620% | ||
| $0-100% | $5.5M-81.7% | $2.6M-51.9% | $14M— | $3M-72.2% | ||
| $300K+400% | $0-100% | $4.5M— | $3.5M+40.0% | -$100K-104% | ||
| $12.5M-2.3% | $100K-99.0% | $24.4M+9.9% | $6M-54.9% | $12.8M+1,500% | ||
| $55.2M+210% | $47.5M+35.7% | $22.8M+117% | $52.8M+252% | $17.8M+612% | ||
| $710.1M-14.2% | $706.6M+171% | $669.7M+344% | $611.8M+165% | $827.9M+426% | ||
| $1.7M+143% | -$3.1M— | -$2.4M+76.5% | $1M-86.1% | $700K+450% | ||
| $68.9M+38.1% | $32.3M+12.9% | $34.7M+0.6% | $57.2M+5.3% | $49.9M-19.6% | ||
| $0-100% | —— | —— | —— | $36.3M— | ||
| $100M+100% | —— | -$50M-150% | —— | $50M— | ||
| $35.1M— | $0-100% | —— | —— | $0— | ||
| -$21.1M-109% | $353.5M— | $516.2M+72.1% | $240.9M-15.8% | $224.4M+289% | ||
| -$21.1M-109% | $353.5M— | $516.2M+72.1% | $240.9M-15.8% | $224.4M+289% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Edwards Lifesciences generate?
- Edwards Lifesciences (EW) generated $1.4B in operating cash flow over the trailing twelve months.
- What is Edwards Lifesciences's free cash flow?
- After $269.1M of capital expenditures, Edwards Lifesciences's free cash flow was $1.1B over the trailing twelve months, up 57.5% year over year.
- Where does Edwards Lifesciences's cash flow data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
